Feb 2022

TMed Technology was founded in February 2022 by two sleep physicians. Their vision is to support Canadian CPAP vendors during a global supply shortage caused by the pandemic and a massive recall of up to 15 million Philips CPAP devices in 2021.

Jun 2022

TMed Technology obtained our Medical Device Establishment License (MDEL) in June 2022, ensuring compliance with Health Canada’s regulations. This certification allows us to distribute safe and reliable CPAP devices in Canada.

Feb 2023

In February 2023, Health Canada authorized TMed Technology for the exceptional importation of a series of PAP device models. These devices support various therapy modes, including CPAP, APAP, BPAP-S, BPAP-ST, BPAP-T, and Auto BPAP-S.

Jul 2023

Health Canada extended the exceptional importation and sale license for TMed Technology's PAP devices, allowing us to better fulfill market needs.

Aug 2024

The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) offers advisory services and funding to support the growth of Canadian small and medium-sized businesses. In August 2024, TMed Technology participated in the NRC IRAP IP Assist L1 Program.

Sep 2024

In September 2024, TMed Technology achieved MDSAP certification, reaffirming our commitment to quality and safety in medical device manufacturing and distribution. This certification ensures our compliance with ISO 13485 and regulatory standards in Canada, the U.S., Australia, Brazil, and Japan, enabling us to deliver reliable and trusted products to the global market.

Building on our commitment to innovation and growth, TMed Technology was accepted into the Fundable program through Okanagan Accelerate, exploring various pathways to develop an investable venture.

Feb 2025

TMed Technology successfully passed the audit to expand our quality management system's scope to include the design, development, manufacturing, and distribution of PAP devices, accessories, and software for sleep therapy and diagnosis. The updated MDSAP certification is expected by March/April 2025.

Following our completion of the NRC IRAP IP Assist L1 Program in August 2024, TMed Technology advanced to the IP Assist L2 Program to develop an intellectual property strategy aligned with our business goals.

In addition, TMed Technology was accepted into the Innovation Acceleration MEDTEQ+ (IAM) program, which provides Canadian healthcare technology SMEs with resources to accelerate marketing and business growth.

Mar 2025

TMed Technology was accepted into the Canada-Taiwan 2024-25 Collaborative Industrial R&D Call for Proposals and successfully passed the initial screening. We will submit a proposal by May 2025, outlining a collaboration plan with GrowTrend BioMedical Inc. and Taipei Medical University.